Amplified genes involved in cancer
OwnerJing Li, Scott Powers +2inventors
InventorsJing Li, Scott Powers, Wun Chey Sin, Jianxin Yang
Life of this patent
Estimating the term…
Abstract
There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing genes, which are amplified in many types of cancer. The amplified genes, their expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or as vaccines; they also are used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.
Claims134
A method for diagnosing a cancer in a mammal, comprising:
- a) determining SPHK1 gene copy number in a test sample from a region of the mammal that is suspected to be precancerous or cancerous, thereby generating data for a test gene copy number;
- and
- b) comparing the test gene copy number to data for a control gene copy number, wherein an amplification of the gene in the test sample relative to the control indicates the presence of a precancerous lesion or a cancer in the mammal.
A method for inhibiting cancer or precancerous growth in a mammalian tissue, comprising contacting the tissue with an inhibitor that interacts with SPHK1 DNA or RNA and thereby inhibits SPHK1 gene function.
A method for inhibiting cancer or precancerous growth in a mammalian tissue, comprising contacting the tissue with an inhibitor of SPHK1 protein.
A method for diagnosing a cancer in a mammal, comprising:
- a) determining the level of SPHK1 in a test sample from a region of the mammal that is suspected to be precancerous or cancerous, thereby generating data for a test level;
- and
- b) comparing the test level to data for a control level, wherein an elevated test level of the test sample relative to the control level indicates the presence of a precancerous lesion or a cancer in the mammal.
A method of administering siRNA to a patient in need thereof, wherein the siRNA molecule is delivered in the form of a naked oligonucleotide or a vector, wherein the siRNA interacts with SPHK1 gene or SPHK1 mRNA transcript.
A method of blocking in vivo expression of a gene by administering a vector encoding SPHK1 siRNA.
A method of screening a test molecule for SPHK1 antagonist activity comprising the steps of:
- a) contacting the molecule with a cancer cell;
- b) determining the level of SPHK1 in the cell, thereby generating data for a test level;
- and
- c) comparing the test level to the SPHK1 level of the cancer cell prior to contacting the test molecule, wherein a decrease in SPHK1 in the test level indicates SPHK1 antagonist activity of the test molecule.
A method of screening a test molecule for SPHK1 antagonist activity comprising the steps of:
- a) contacting the molecule with SPHK1;
- and
- b) determining the effect of the test molecule on SPHK1.
A method of determining whether a test molecule has SPHK1 antagonist activity, wherein the method comprises:
- a) determining the level of SPHK1 in a test sample containing cancer cells, thereby generating data for a control level;
- b) contacting the molecule with the test sample to generate data for a test level;
- and
- c) comparing the control level to the test level, wherein no decrease in SPHK1 in the test level as compared to the control level indicates that the test molecule has no SPHK1 antagonist activity.
A method for selecting test molecules having SPHK1 antagonist activity, wherein the method comprises:
- a) determining the level of SPHK1 in a test sample containing cancer cells, thereby generating data for a control level;
- b) contacting the molecule with the test sample to generate data for a test level;
- c) comparing the control level to test level, wherein no decrease in SPHK1 in the test level as compared to the control level indicates that the test molecule has no SPHK1 antagonist activity;
- and
- d) eliminating the test molecule from further evaluation or study.
A method for determining the efficacy of a therapeutic treatment regimen in a patient, comprising:
- a) measuring the SPHK1 gene copy number in a first sample obtained from a patient, thereby generating an initial level;
- b) administering the treatment regimen to the patient;
- c) measuring the SPHK1 gene copy number in a second sample from the patient at a time following administration of the treatment regimen, thereby generating a test level;
- and
- d) comparing the initial and test levels, wherein a decrease in the gene copy number level in the test level relative to the initial level indicates that the treatment regimen is effective in the patient.
A method for determining the efficacy of a therapeutic treatment regimen in a patient, comprising:
- a) measuring at least one of SPHK1 mRNA or SPHK1 expression levels in a first sample obtained from the patient, thereby generating data for a pre-treatment level;
- b) administering the treatment regimen to the patient;
- c) measuring at least one of SPHK1 mRNA or SPHK1 expression levels in a second sample from the patient at a time following administration of the treatment regimen, thereby generating data for a test level;
- and
- d) comparing the pre-treatment level to the test level, wherein data showing no decrease in the test level relative to the pre-treatment level indicates that the treatment regimen is not effective in the patient.
A method for selecting test molecules having a therapeutic effect in a patient, comprising:
- a) measuring at least one of SPHK1 mRNA or SPHK1 expression levels in a first sample obtained from the patient, thereby generating data for a pre-treatment level;
- b) administering the test molecule to the patient;
- c) measuring at least one of SPHK1 mRNA or SPHK1 expression levels in a second sample from the patient at a time following administration of the test molecule, thereby generating data for a test level;
- d) comparing the pre-treatment level to the test level, wherein data showing no decrease in the test level relative to the pre-treatment level indicates that the test molecule is not effective in the patient;
- and
- e) eliminating the test molecule from further evaluation or study.
A method for diagnosing a cancer in a mammal, comprising:
- a) determining EDG4 gene copy number in a test sample from a region of the mammal that is suspected to be precancerous or cancerous, thereby generating data for a test gene copy number;
- and
- b) comparing the test gene copy number to data for a control gene copy number, wherein an amplification of the gene in the test sample relative to the control indicates the presence of a precancerous lesion or a cancer in the mammal.
A method for inhibiting cancer or precancerous growth in a mammalian tissue, comprising contacting the tissue with an inhibitor that interacts with EDG4 DNA or RNA and thereby inhibits EDG4 gene function.
A method for inhibiting cancer or precancerous growth in a mammalian tissue, comprising contacting the tissue with an inhibitor of EDG4 protein.
A method for diagnosing a cancer in a mammal, comprising:
- a) determining the level of EDG4 in a test sample from a region of the mammal that is suspected to be precancerous or cancerous, thereby generating data for a test level;
- and
- b) comparing the test level to data for a control level, wherein an elevated test level of the test sample relative to the control level indicates the presence of a precancerous lesion or a cancer in the mammal.
A method of administering siRNA to a patient in need thereof, wherein the siRNA molecule is delivered in the form of a naked oligonucleotide or a vector, wherein the siRNA interacts with EDG4 gene or EDG4 mRNA transcript.
A method of blocking in vivo expression of a gene by administering a vector encoding EDG4 siRNA.
A method of screening a test molecule for EDG4 antagonist activity comprising the steps of:
- a) contacting the molecule with a cancer cell;
- b) determining the level of EDG4 in the cell, thereby generating data for a test level;
- and
- c) comparing the test level to the EDG4 level of the cancer cell prior to contacting the test molecule, wherein a decrease in EDG4 in the test level indicates EDG4 antagonist activity of the test molecule.
A method of screening a test molecule for EDG4 antagonist activity comprising the steps of:
- a) contacting the molecule with EDG4;
- and
- b) determining the effect of the test molecule on EDG4.
A method of determining whether a test molecule has EDG4 antagonist activity, wherein the method comprises:
- a) determining the level of EDG4 in a test sample containing cancer cells, thereby generating data for a control level;
- b) contacting the molecule with the test sample to generate data for a test level;
- and
- c) comparing the control level to the test level, wherein no decrease in EDG4 in the test level as compared to the control level indicates that the test molecule has no EDG4 antagonist activity.
A method for selecting test molecules having EDG4 antagonist activity, wherein the method comprises:
- a) determining the level of EDG4 in a test sample containing cancer cells, thereby generating data for a control level;
- b) contacting the molecule with the test sample to generate data for a test level;
- c) comparing the control level to test level, wherein no decrease in EDG4 in the test level as compared to the control level indicates that the test molecule has no EDG4 antagonist activity;
- and
- d) eliminating the test molecule from further evaluation or study.
A method for determining the efficacy of a therapeutic treatment regimen in a patient, comprising:
- a) measuring the EDG4 gene copy number in a first sample obtained from a patient, thereby generating an initial level;
- b) administering the treatment regimen to the patient;
- c) measuring the EDG4 gene copy number in a second sample from the patient at a time following administration of the treatment regimen, thereby generating a test level;
- and
- d) comparing the initial and test levels, wherein a decrease in the gene copy number level in the test level relative to the initial level indicates that the treatment regimen is effective in the patient.
A method for determining the efficacy of a therapeutic treatment regimen in a patient, comprising:
- a) measuring at least one of EDG4 mRNA or EDG4 expression levels in a first sample obtained from the patient, thereby generating data for a pre-treatment level;
- b) administering the treatment regimen to the patient;
- c) measuring at least one of EDG4 mRNA or EDG4 expression levels in a second sample from the patient at a time following administration of the treatment regimen, thereby generating data for a test level;
- and
- d) comparing the pre-treatment level to the test level, wherein data showing no decrease in the test level relative to the pre-treatment level indicates that the treatment regimen is not effective in the patient.
A method for selecting test molecules having a therapeutic effect in a patient, comprising:
- a) measuring at least one of EDG4 mRNA or EDG4 expression levels in a first sample obtained from the patient, thereby generating data for a pre-treatment level;
- b) administering the test molecule to the patient;
- c) measuring at least one of EDG4 mRNA or EDG4 expression levels in a second sample from the patient at a time following administration of the test molecule, thereby generating data for a test level;
- d) comparing the pre-treatment level to the test level, wherein data showing no decrease in the test level relative to the pre-treatment level indicates that the test molecule is not effective in the patient;
- and
- e) eliminating the test molecule from further evaluation or study.
A method for diagnosing a cancer in a mammal, comprising:
- a) determining EDG5 gene copy number in a test sample from a region of the mammal that is suspected to be precancerous or cancerous, thereby generating data for a test gene copy number;
- and
- b) comparing the test gene copy number to data for a control gene copy number, wherein an amplification of the gene in the test sample relative to the control indicates the presence of a precancerous lesion or a cancer in the mammal.
A method for inhibiting cancer or precancerous growth in a mammalian tissue, comprising contacting the tissue with an inhibitor that interacts with EDG5 DNA or RNA and thereby inhibits EDG5 gene function.
A method for inhibiting cancer or precancerous growth in a mammalian tissue, comprising contacting the tissue with an inhibitor of EDG5 protein.
A method for diagnosing a cancer in a mammal, comprising:
- a) determining the level of EDG5 in a test sample from a region of the mammal that is suspected to be precancerous or cancerous, thereby generating data for a test level;
- and
- b) comparing the test level to data for a control level, wherein an elevated test level of the test sample relative to the control level indicates the presence of a precancerous lesion or a cancer in the mammal.
A method of administering siRNA to a patient in need thereof, wherein the siRNA molecule is delivered in the form of a naked oligonucleotide or a vector, wherein the siRNA interacts with EDG5 gene or EDG5 mRNA transcript.
A method of blocking in vivo expression of a gene by administering a vector encoding EDG5 siRNA.
A method of screening a test molecule for EDG5 antagonist activity comprising the steps of:
- a) contacting the molecule with a cancer cell;
- b) determining the level of EDG5 in the cell, thereby generating data for a test level;
- and
- c) comparing the test level to the EDG5 level of the cancer cell prior to contacting the test molecule, wherein a decrease in EDG5 in the test level indicates EDG5 antagonist activity of the test molecule.
A method of screening a test molecule for EDG5 antagonist activity comprising the steps of:
- a) contacting the molecule with EDG5;
- and
- b) determining the effect of the test molecule on EDG5.
A method of determining whether a test molecule has EDG5 antagonist activity, wherein the method comprises:
- a) determining the level of EDG5 in a test sample containing cancer cells, thereby generating data for a control level;
- b) contacting the molecule with the test sample to generate data for a test level;
- and
- c) comparing the control level to the test level, wherein no decrease in EDG5 in the test level as compared to the control level indicates that the test molecule has no EDG5 antagonist activity.
A method for selecting test molecules having EDG5 antagonist activity, wherein the method comprises:
- a) determining the level of EDG5 in a test sample containing cancer cells, thereby generating data for a control level;
- b) contacting the molecule with the test sample to generate data for a test level;
- c) comparing the control level to test level, wherein no decrease in EDG5 in the test level as compared to the control level indicates that the test molecule has no EDG5 antagonist activity;
- and
- d) eliminating the test molecule from further evaluation or study.
A method for determining the efficacy of a therapeutic treatment regimen in a patient, comprising:
- a) measuring the EDG5 gene copy number in a first sample obtained from a patient, thereby generating an initial level;
- b) administering the treatment regimen to the patient;
- c) measuring the EDG5 gene copy number in a second sample from the patient at a time following administration of the treatment regimen, thereby generating a test level;
- and
- d) comparing the initial and test levels, wherein a decrease in the gene copy number level in the test level relative to the initial level indicates that the treatment regimen is effective in the patient.
A method for determining the efficacy of a therapeutic treatment regimen in a patient, comprising:
- a) measuring at least one of EDG5 mRNA or EDG5 expression levels in a first sample obtained from the patient, thereby generating data for a pre-treatment level;
- b) administering the treatment regimen to the patient;
- c) measuring at least one of EDG5 mRNA or EDG5 expression levels in a second sample from the patient at a time following administration of the treatment regimen, thereby generating data for a test level;
- and
- d) comparing the pre-treatment level to the test level, wherein data showing no decrease in the test level relative to the pre-treatment level indicates that the treatment regimen is not effective in the patient.
A method for selecting test molecules having a therapeutic effect in a patient, comprising:
- a) measuring at least one of EDG5 mRNA or EDG5 expression levels in a first sample obtained from the patient, thereby generating data for a pre-treatment level;
- b) administering the test molecule to the patient;
- c) measuring at least one of EDG5 mRNA or EDG5 expression levels in a second sample from the patient at a time following administration of the test molecule, thereby generating data for a test level;
- d) comparing the pre-treatment level to the test level, wherein data showing no decrease in the test level relative to the pre-treatment level indicates that the test molecule is not effective in the patient;
- and
- e) eliminating the test molecule from further evaluation or study.
A method for diagnosing a cancer in a mammal, comprising:
- a) determining EDG8 gene copy number in a test sample from a region of the mammal that is suspected to be precancerous or cancerous, thereby generating data for a test gene copy number;
- and
- b) comparing the test gene copy number to data for a control gene copy number, wherein an amplification of the gene in the test sample relative to the control indicates the presence of a precancerous lesion or a cancer in the mammal.
A method for inhibiting cancer or precancerous growth in a mammalian tissue, comprising contacting the tissue with an inhibitor that interacts with EDG8 DNA or RNA and thereby inhibits EDG8 gene function.
A method for inhibiting cancer or precancerous growth in a mammalian tissue, comprising contacting the tissue with an inhibitor of EDG8 protein.
A method for diagnosing a cancer in a mammal, comprising:
- a) determining the level of EDG8 in a test sample from a region of the mammal that is suspected to be precancerous or cancerous, thereby generating data for a test level;
- and
- b) comparing the test level to data for a control level, wherein an elevated test level of the test sample relative to the control level indicates the presence of a precancerous lesion or a cancer in the mammal.
A method of administering siRNA to a patient in need thereof, wherein the siRNA molecule is delivered in the form of a naked oligonucleotide or a vector, wherein the siRNA interacts with EDG8 gene or EDG8 mRNA transcript.
A method of blocking in vivo expression of a gene by administering a vector encoding EDG8 siRNA.
A method of screening a test molecule for EDG8 antagonist activity comprising the steps of:
- a) contacting the molecule with a cancer cell;
- b) determining the level of EDG8 in the cell, thereby generating data for a test level;
- and
- c) comparing the test level to the EDG8 level of the cancer cell prior to contacting the test molecule, wherein a decrease in EDG8 in the test level indicates EDG8 antagonist activity of the test molecule.
A method of screening a test molecule for EDG8 antagonist activity comprising the steps of:
- a) contacting the molecule with EDG8;
- and
- b) determining the effect of the test molecule on EDG8.
A method of determining whether a test molecule has EDG8 antagonist activity, wherein the method comprises:
- a) determining the level of EDG8 in a test sample containing cancer cells, thereby generating data for a control level;
- b) contacting the molecule with the test sample to generate data for a test level;
- and
- c) comparing the control level to the test level, wherein no decrease in EDG8 in the test level as compared to the control level indicates that the test molecule has no EDG8 antagonist activity.
A method for selecting test molecules having EDG8 antagonist activity, wherein the method comprises:
- a) determining the level of EDG8 in a test sample containing cancer cells, thereby generating data for a control level;
- b) contacting the molecule with the test sample to generate data for a test level;
- c) comparing the control level to test level, wherein no decrease in EDG8 in the test level as compared to the control level indicates that the test molecule has no EDG8 antagonist activity;
- and
- d) eliminating the test molecule from further evaluation or study.
A method for determining the efficacy of a therapeutic treatment regimen in a patient, comprising:
- a) measuring the EDG8 gene copy number in a first sample obtained from a patient, thereby generating an initial level;
- b) administering the treatment regimen to the patient;
- c) measuring the EDG8 gene copy number in a second sample from the patient at a time following administration of the treatment regimen, thereby generating a test level;
- and
- d) comparing the initial and test levels, wherein a decrease in the gene copy number level in the test level relative to the initial level indicates that the treatment regimen is effective in the patient.
A method for determining the efficacy of a therapeutic treatment regimen in a patient, comprising:
- a) measuring at least one of EDG8 mRNA or EDG8 expression levels in a first sample obtained from the patient, thereby generating data for a pre-treatment level;
- b) administering the treatment regimen to the patient;
- c) measuring at least one of EDG8 mRNA or EDG8 expression levels in a second sample from the patient at a time following administration of the treatment regimen, thereby generating data for a test level;
- and
- d) comparing the pre-treatment level to the test level, wherein data showing no decrease in the test level relative to the pre-treatment level indicates that the treatment regimen is not effective in the patient.
A method for selecting test molecules having a therapeutic effect in a patient, comprising:
- a) measuring at least one of EDG8 mRNA or EDG8 expression levels in a first sample obtained from the patient, thereby generating data for a pre-treatment level;
- b) administering the test molecule to the patient;
- c) measuring at least one of EDG8 mRNA or EDG8 expression levels in a second sample from the patient at a time following administration of the test molecule, thereby generating data for a test level;
- d) comparing the pre-treatment level to the test level, wherein data showing no decrease in the test level relative to the pre-treatment level indicates that the test molecule is not effective in the patient;
- and
- e) eliminating the test molecule from further evaluation or study.
A method for treating cancer or precancerous growth in a mammalian tissue, comprising contacting the tissue with an antibody to S1P protein.
A method of treating cancer in a patient comprising administering the patient an effective amount of an anti-S1P antibody.
Dependencies are inferred from the claim text.